Health Technology

PointClickCare Launches Integrated Virtual Health Solution for Long-Term and Post-Acute Care Providers

PointClickCare Launches

PointClickCare Technologies, a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights announced the launch of its Virtual Health offering – an integrated telemedicine solution to the Skilled Nursing Facilities market. With the help of partner Sound Physicians, this technology is currently being implemented in more than half of the states across the U.S. Over the next two days at the AHCA/NCAL Convention and Expo, PointClickCare will be showcasing the innovative ways providers can better achieve quality care and reach the full potential of virtual health in the post‐acute setting.

According to the Forrester U.S. Tech Outlook, 2022 Report, investment in virtual health, remote monitoring, and hospital-at-home, are spending priorities in 2022. Forrester analysts have confirmed that these technologies have the power to reduce the cost of administrative complexity, which is currently $265 billion.

Recent data from the US Department of Health & Human Services explains that the share of Medicare visits conducted through telehealth rose to 52.7 million in 2020, from approximately 840,000 in 2019. Knowing that telehealth has become an increasingly important, yet sometimes complicated component of healthcare, PointClickCare has developed an alternative to traditional telehealth by applying technological improvements to offer an integrated solution.

Telehealth is no longer a futuristic concept in long-term care, it’s table stakes. Our customers continue to navigate between care settings and our team has sought to innovate and push the envelope on providing virtual care. We’re proud to announce this technology that has been specifically designed to meet the mission‐critical needs of post‐acute providers to improve clinical care and reduce healthcare costs, consistently driving down hospital readmissions by 30%.”

Travis Palmquist, Senior Vice President and General Manager of Senior Care at PointClickCare

With PointClickCare’s Virtual Health offering, providers can now

  • Improve patient care & staff satisfaction: By streamlining operations through a sophisticated level of integration into existing workflows, care teams have access to shared patient records, and can cut down on administrative tasks and can focus on what matters most – patient care.
  • Reduce healthcare service costs: With the ability to “treat in place,” facilities experience stabilized occupancy rates and can reduce the need for after-hours readmissions or emergency room department transfers, ultimately lowering overall costs.

“The ongoing staffing crisis has created a new level of pressure for our staff. With PointClickCare’s Virtual Health solution, our care teams can access an on-shift physician with just one click, streamlining operations and cutting down on a lot of the administrative burdens we are faced with, all while ensuring our patients are getting the best quality of care, any time,” said Kevin Baxter, Vice President of Operations at Health Services Management.

About PointClickCare
PointClickCare is a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights at any stage of a patient’s healthcare journey. PointClickCare’s single platform spans the care continuum, fostering proactive, holistic decision‐making and improved outcomes for all. Over 27,000 long‐term post‐acute care providers, and 2,700 hospitals use PointClickCare today, enabling care collaboration and value‐based care delivery for millions of lives across North America.

Spotlight

Other News
Digital Healthcare

Syra Health Wraps Up a Successful 2023, including New Contracts, Contract Extensions, and the introduction of new Healthcare Innovations

Syra Health | January 04, 2024

Syra Health Corp. a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, is excited to summarize its significant accomplishments and the introduction of its innovative solutions across the Company's six business units. Within its Behavioral and Mental Health Business Unit, Syra Health Launched Syrenity, the Company's flagship mental and behavioral product, focused on preventing mental health crises. Syrenity is evidence-based and AI-backed, offering continual monitoring and cognitive therapy interventions. Syrenity also integrates with telehealth, allowing for easy access to licensed mental health professionals when treatment is necessary. Entered into a strategic agreement with E&I Cooperative Services (E&I) which extended Syrenity's reach to over 6,000 colleges and universities nationwide, that make up E&I's membership. Secured a five-year, $4.75 million contract with the District of Columbia's Department of Behavioral Health, to support vital mental health programs in communities. Entered into a one-year agreement with the County of Camden Psychological Screening and Evaluation Services to provide mental health screening and evaluations to Camden County, New Jersey law enforcement personnel. Received a contract from the Mississippi Department of Human Services (MDHS) to provide behavioral and mental health services to the Oakley Youth Development Center and other locations as directed by MDHS. Across its Digital Health Business Unit, Syra Health Launched CarePlus, an easy-to-use, secure, and scalable electronic medical record (EMR) system for small and mid-sized healthcare organizations. CarePlus is affordable and accessible by simplifying clinical workflows, integrating labs, radiology, and telehealth. Unveiled SyraBot, a digital health product that uses human-centric AI to deliver conversational and immediate responses to inquiries made through any healthcare organization's website. SyraBot provides real-time access to information users need, twenty-four hours a day, seven days a week in up to 200 languages. As part of its Population Health Business Unit, Syra Health Received a two-year contract extension, worth up to $636,000 with the Indiana Division of Mental Health and Addiction and Family and Social Services Administration, to chair and manage the State of Indiana's Epidemiological Outcomes Workgroup. Secured a five-year contract worth $275,000 with the City of San Antonio to evaluate its Racial and Ethnic Approaches to Community Health (REACH) Healthy Neighborhoods Project. Across its Health Education Business Unit, Syra Health Entered into a new strategic agreement with the Maricopa County Department of Public Health in Arizona where Syra Health experts trained over 100 public health staff on best practices for implementing health equity. As part of its Healthcare Workforce Business Unit, Syra Health Won a contract with Osawatomie State Hospital and Adair Acute Care in Kansas, to deploy licensed healthcare professionals to deliver vital social and therapy services. Secured contracts across Oklahoma, Virginia, and Alabama to deliver healthcare staffing solutions to correctional facilities. Provides on-demand temporary medical personnel, including nurses and nurses' aides, for two veteran homes in Ohio and one in Indiana. Delivers direct care staffing for the Department of Health and Human Resources Purchasing Division in the state of West Virginia. Expanded its Healthcare Workforce Solutions to include a new technology platform for employers and those seeking new positions, plus engagement and concierge services. Syra Health Announced its Expansion into Federal Government Contracts, making Federal Government Solutions the Company's Sixth Business Unit Syra Health expanded its reach beyond state and local governments to include supplying its products and services to the federal government. Milestones On September 29, 2023, Syra Health became a publicly traded company on the Nasdaq, under the ticker symbol "SYRA. In October 2023, Syra Health successfully closed on $6.7 million in IPO financing. Syra Health's third-quarter revenue increased by 4%. Importantly, the Company saw a significant rise in gross profit margins from 27.3% to 35.1% versus the same period the year prior. "2023 was a transformative year for Syra Health," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "We are incredibly proud of our team's commitment which has enabled us to secure new contracts and launch innovative products. As we step into the new year, we are driven by a profound commitment to continue addressing the most significant healthcare challenges and to improving healthcare for all." About Syra Health Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government.

Read More

Medical Devices

Canon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems

Canon Medical Systems | January 15, 2024

Canon Medical Systems Corporation and Olympus Corporation announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems. Canon Medical will develop and manufacture diagnostic ultrasound systems used in Endoscopic Ultrasonography1 (EUS), and Olympus will perform the sales and marketing efforts. The aim of this collaboration between Canon's Aplio i8002 diagnostic ultrasound system for EUS and Olympus' Ultrasound Endoscope3 is to provide the market with advanced EUS equipment capable of delivering high-quality image diagnoses. Canon Medical and Olympus are focusing on technological advancements and enhancing diagnostic performance in the EUS field, with plans for global expansion, starting in Japan and Europe. Canon Medical has a history of more than 100 years in the diagnostic imaging systems business, including X-ray diagnostic systems, CT, MRI, and ultrasound diagnostic systems, and provides products and services to more than 150 countries and regions worldwide. Canon Medical has been a leading company in the development of diagnostic ultrasound systems since the 1960s and has pioneered the development of A-mode (Amplitude display mode) systems for neurosurgery and linear electronic scanning systems, among others. Canon Medical's strengths lie in its advanced ultrasound image quality and proprietary technologies, such as D-THI, an image quality enhancement technology, and SMI, an imaging technology that enables the delineation of extremely slow and fine blood flow, which has been difficult to image in the past. Olympus has contributed to elevating the standard of care through early detection, diagnosis and staging, and minimally invasive treatment since developing the world’s first practical gastrocamera. In the field of EUS, Olympus has worked closely with physicians to develop new equipment to enhance imaging and diagnostic methods and expand procedures, helping gain and maintain a high share of the global market. Through our collaboration, the two companies will achieve further qualitative improvements in the quality of images and performance in diagnosis and minimally invasive treatment of EUS, ultimately contributing to facilitate the early detection of diseases. Comment from Toshio Takiguchi, President and CEO, Canon Medical Systems Corporation “We have been promoting our business with diagnostic imaging at its core under the philosophy of 'Made for Life,' which expresses our desire to contribute to medical care that protects precious lives. We have a long history in diagnostic ultrasound systems and have developed unique technologies that contribute to the early detection of diseases in cooperation with doctors around the world. We are very pleased to collaborate with Olympus, a leading endoscope manufacturer, in the EUS field, which we have not been able to cover adequately until now, to deliver superior solutions to more patients.” Comment from Frank Drewalowski, Executive Officer and Endoscopic Solutions Division Head, Olympus Corporation “Olympus aims to improve patients’ quality of life through early diagnosis made available with Endoscopic Ultrasound Systems. In the field of EUS, diagnostic ultrasound systems are very important, and we are pleased to have a cooperative relationship with Canon Medical, which has advanced ultrasound imaging technology. Canon Medical and Olympus will continue to introduce products and technology that address the needs of the patients, healthcare professionals, and the broader medical industry.” This examination uses ultrasound attached to the tip of an endoscope to observe the outer organs (pancreas, gallbladder, bile ducts, liver, etc.) from the stomach and duodenum. Compared to the approach from the body surface, the target organs can be observed at close range, allowing detailed diagnosis with clearer images. In the diagnosis of pancreatic cancer, EUS is recognized as having the same diagnostic capability as contrast-enhanced CT and MRI in the "Guidelines for Pancreatic Cancer Treatment (2022)" in Japan. EUS-FNA (Endoscopic Ultrasonography-FNA: a test to collect tumor cells using an ultrasound endoscope) enables qualitative tissue diagnosis by minimally invasive cell and tissue collection and is established worldwide as a diagnostic method when pancreatic cancer is suspected. In addition to endoscopic retrograde cholangiopancreatography (ERCP), which is the first choice for stent placement for obstructive jaundice, endoscopic ultrasound-assisted biliary drainage (EUS-BD) using the EUS-FNA technique is now available. With the advent of these devices, the endoscopic treatment area of Interventional EUS has been attracting increasing attention in recent years. About Canon Medical Systems Canon Medical offers a full range of diagnostic medical imaging solutions including CT, Diagnostic and Interventional X-ray, Ultrasound and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. At Canon Medical, we work hand in hand with our partners - our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life About Olympus At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

Read More

Health Technology

Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Beckman Coulter Diagnostics | January 30, 2024

Beckman Coulter Diagnostics, a clinical diagnostics leader, will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024. The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories. "Healthcare systems around the world are strategically adopting hub-and-spoke models for better efficiency and healthcare access," said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics. "Hub-and-spoke clinical laboratory models optimize resources to improve access to testing services and enhance overall standardization for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes." The DxC 500 AU Chemistry Analyzer features advanced automation technology, onboard guided workflows, and standardized reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high quality Six Sigma performance, supporting confidence in clinical results, reducing QC trouble shooting and lab operational costs. "Our Six Sigma assessment has shown that the DxC 500 AU analyzer easily exceeds the demands of the new, more stringent CLIA 2024 performance specifications," stated Sten Westgard, Director of Client Services and Technology for Westgard QC. The DxC 500 AU Chemistry Analyzer is for in vitro diagnostic use only. It is available throughout North America and the Middle East. Global commercial availability is planned for March 2024. About Beckman Coulter. Inc. A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, Calif., with more than 11,000 global team members, Beckman Coulter Diagnostics is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. ©2024 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Read More

Health Technology

Axxess Launches New Axxess Connect Solution to Accelerate Health Information Exchange

Axxess | January 23, 2024

Axxess, the leading global technology innovator for healthcare at home, launched a new product called Axxess Connect, a groundbreaking interoperability solution. This new product will revolutionize the way Axxess users connect and share data with healthcare providers and specialists, further enhancing care coordination, improving patient outcomes and driving the future by enabling new care models and value-based care. "Axxess Connect is a new benchmark for interoperability in healthcare," says Tim Ingram, Executive Vice President of Interoperability at Axxess. "By working with our partner Kno2 we can now connect our solutions to help accelerate the exchange of health information securely across any network. This means our clients will have easier access to a broader range of providers and specialists, making data sharing and referrals more efficient." By being Kno2 Connected™, Axxess Connect, enables the secure, effortless, and maximized exchange of patient information across patients, providers, payers and HIT vendors. ­­­­The solution meets data security and compliance requirements in accordance with HITRUST and HIPAA regulation for privacy, data sharing and healthcare communication standards supported by national and regional frameworks including Direct Trust, Carequality and most recently, TEFCA. This ensures that patient data is interoperable, secured and protected when shared across systems. "Our collaboration with Kno2 not only improves the overall experience for our users, but it also reduces the administrative load on healthcare providers," said Ingram. "By minimizing time spent on administrative tasks, our clients can focus more on providing quality patient care." Added Theresa Bell, Co-founder, President and Chief Technology Officer of Kno2: "By seamlessly connecting Axxess users with healthcare providers and specialists, we are breaking down barriers and revolutionizing the way data is shared in every care setting. Axxess Connect represents the power of the partnership and the value of being Kno2 Connected. Together, we are revolutionizing care delivery and thoughtfully solving healthcare's biggest problems." Axxess Connect will first be available to Axxess Palliative Care clients before eventually being rolled out to the entire Axxess suite of solutions for home health, hospice and home care. About Axxess Axxess is the leading global technology innovator for healthcare at home, focused on solving the most complex industry challenges. Trusted by more than 9,000 organizations that serve more than 5 million patients worldwide, Axxess offers a complete suite of easy-to-use software solutions that empower home health, home care, hospice, and palliative providers to make healthcare in the home human again. Multiple independent certifications have confirmed that Axxess has the most secure and industry-compliant software available for providers. The company's collaborative culture focused on innovation and excellence is recognized nationally as a "Best Place to Work."

Read More